Dubbed the worst Ebola outbreak in history, more than 2,000 people in West Africa have died from the virus.
But the fight against the deadly outbreak could be gaining a new weapon: A vaccine is being tested on humans for the first time.
The U.S. National Institutes of Health said animal trials using macaques showed the vaccine can make recipients much less vulnerable to the virus, though the effect began to wear off around the 10-month mark. (Video via BBC)
But the director of the U.S. National Institute of Allergy and Infectious Diseases told the BBC,"The good part of this vaccine is that at five weeks or earlier you get full protection. The sobering news is the durability isn't great, but if you give a boost, a second shot, you make it really durable."
The NIH along with the World Health Organization and several U.K. agencies all partnered with pharmaceutical company GlaxoSmithKline to create and test the vaccine.
But it will still be some time before it goes into widespread use. GSK says on its website: "Clinical development for a new vaccine is a long, complex process, often lasting 10 or more years. It is difficult to accelerate this process because of the many important steps that a candidate vaccine must go through to ensure that it is safe and effective."
Health officials worldwide are trying to speed things up as best they can because of just how severe the West African outbreak is.
Last month, the WHO approved the use of experimental drugs to help combat the disease. And last week it added a new experimental treatment to the list: using blood from Ebola survivors to help new victims. (Video via Euronews)
The NIH is also collaborating with at least two other companies that are working on their own vaccines, though none of the rest are up to the human stage of testing yet.
Thank you for reading the Dayton Daily News and for supporting local journalism. Subscribers: log in for access to exclusive deals and newsletters.
Thank you for supporting in-depth local journalism with your subscription to the Dayton Daily News. Get more news when you want it with email newsletters just for subscribers. Sign up here.